Table 3.
Number of Lesions That Achieved Resolution Each Follow-Up Day
| Day | Control (n=35) | 700DMNTA (n=35) | 1000DMNTA (n=35) | 700DMN (n=35) | P-value* |
|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | N/A |
| 2 | 0 | 4 (11.42) | 3 (8.75) | 0 | <0.001 |
| 3 | 2 (5.71) | 9 (25.71) | 11 (31.42) | 6 (17.14) | 0.042 |
| 7 | 15 (42.85) | 24 (68.57) | 26 (72.28) | 18 (51.42) | 0.013 |
| 14 | 28 (80) | 32 (91.42) | 31 (88.57) | 32 (91.42) | 0.189 |
| 28 | 31 (88.57) | 32 (91.42) | 32 (91.42) | 32 (91.42) | 1.000 |
Notes: *The p-value indicates the between-treatment comparison using linear mixed model analysis, <0.05 is considered statistically significant. Bold font indicates statistical significance.
Abbreviations: 700DMN, 700 µm detachable microneedle patch; 1000DMNTA, 1000 µm detachable microneedle patch containing triamcinolone acetonide; 700DMNTA, 700 µm detachable microneedle patch containing triamcinolone acetonide.